Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
INInovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO)

NASDAQ Global Select · Currency in USD
$0.90 ▲ +0.06 (+6.94%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.91 ▲ +0.01 (+1.42%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$0.84
Open
$0.84
Day's Range
$0.80 – $0.94
52 Week Range
$0.56 – $2.72
Volume
3,900,243
Avg. Volume
3,626,717
Market Cap
$61.98M
Beta (5Y Monthly)
1.61
PE Ratio (TTM)
--
EPS (TTM)
-$0.83
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
$0.07 (7.62%)
Ex-Dividend Date
Sep 28, 2017
1y Target Est
$2.75

Profile: Inovio Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
112
CEO
Jacqueline E. Shea
Website
inovio.com

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$0.20 · Revenue est. $2.27M
DateEst.Actual
Aug 12, 2026-$0.22-$0.07Beat
May 13, 2026-$0.35-$0.28Beat
Mar 12, 2026-$0.37$0.06Beat
Nov 10, 2025-$0.42-$0.87Miss
Aug 12, 2025-$0.63-$0.61Beat
May 13, 2025-$0.74-$0.51Beat

Analyst view

Consensus price target
$2.75 ▲ +206.5%
Range $2.50 – $3.00
Rating: Buy
Buy 59% · Hold 29% · Sell 12%

Get free alerts on INO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.